The present invention relates to compounds of formula (I)
wherein R
1
and R
2
are as defined in the description and claims, and pharmaceutically acceptable salts thereof, for use as therapeutically active substances. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with the modulation of CB1 receptors.
The present invention relates to compounds of formula (I)
wherein R
1
and R
2
are as defined in the description and claims, and pharmaceutically acceptable salts thereof, for use as therapeutically active substances. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with the modulation of CB1 receptors.
( 6-FLU0R0-BENZ0[l, 3] DIOXOLYL) -MORPHOLIN-4-YL-METHANONES AND THEIR USE AS CBl LIGANDS
申请人:F. Hoffmann-La Roche AG
公开号:EP1896445B1
公开(公告)日:2010-11-10
US3985766A
申请人:——
公开号:US3985766A
公开(公告)日:1976-10-12
[EN] ( 6-FLU0R0-BENZ0[l, 3] DIOXOLYL) -MORPHOLIN-4-YL-METHANONES AND THEIR USE AS CBl LIGANDS<br/>[FR] ( 6-FLUOROBENZO[1,3]DIOXOLYL)-MORPHOLIN-4-YL-MÉTHANONES ET LEUR EMPLOI EN TANT QUE LIGANDS DE CBI
申请人:HOFFMANN LA ROCHE
公开号:WO2006136502A1
公开(公告)日:2006-12-28
[EN] The present invention relates to compounds of formula (I) wherein R1 and R2 are as defined in the description and claims, and pharmaceutically acceptable salts thereof, for use as therapeutically active substances. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with the modulation of CBl receptors. [FR] La présente invention concerne des composés de formule (I) où R1 et R2 sont tels que définis dans la description et les revendications, ainsi que des sels de qualité pharmaceutique desdits composés, pour application en tant que substances thérapeutiques actives. Lesdits composés peuvent être employés dans le traitement prophylactique et/ou thérapeutique de maladies liées à la régulation des récepteurs CBI.